Short answer
ALUMIS INC. (ALMS) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Envudeucitinib long-term data highlights highest reported PASI 100 skin clearance among oral psoriasis therapies.
ALUMIS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Envudeucitinib long-term data highlights highest reported PASI 100 skin clearance among oral psoriasis therapies
- Potential competitive positioning for plaque psoriasis treatment and Alumis’s oral immunology pipeline
- Full efficacy, duration, and safety details in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- ONWARD3 showed 54% PASI 100 and 75% PASI 90 after 48 weeks, strengthening envudeucitinib’s differentiation among oral psoriasis therapies
- Approximately 90% of prior PASI 90 responders and 80% of prior PASI 100 responders sustained clearance
- 1,509 patients entered the extension, with an enrollment rollover rate above 85%
- Long-term safety remained consistent with ONWARD1/2, with no new safety signals
- NDA submission targeted for 4Q 2026; LUMUS lupus topline data expected in 3Q 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ALUMIS INC. 8-K filings
Get the next ALMS 8-K as it lands
Follow ALMS for push alerts, or ask the research agent what this filing means.